Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin

被引：0
|
作者：
Mikko Pyykönen
Miika Linna
Markku Tykkyläinen
Eric Delmelle
Tiina Laatikainen
机构：
[1] University of Eastern Finland,Department of Geographical and Historical Studies
[2] Aalto University,Department of Industrial Engineering and Management
[3] Institute of Public Health and Clinical Nutrition,Department of Public Health and Welfare
[4] University of Eastern Finland,undefined
[5] Joint Municipal Authority for North Karelia Social and Health Services,undefined
[6] Finnish Institute for Health and Welfare,undefined
来源：
BMC Health Services Research | / 21卷
关键词：
Real-world data; GIS; Time and travel costs; Cost model; Electronic health records;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
    Pyykonen, Mikko
    Linna, Miika
    Tykkylainen, Markku
    Delmelle, Eric
    Laatikainen, Tiina
    [J]. BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [2] Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin
    Datar, Manasi
    Crivera, Concetta
    Rozjabek, Heather
    Abbass, Ibrahim M.
    Xu, Yihua
    Pasquale, Margaret K.
    Schein, Jeff R.
    Andrews, George A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (05) : 275 - 285
  • [3] Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis
    Kattoor, Ajoe John
    Pothineni, Naga Venkata
    Goel, Akshay
    Syed, Mahanazuddin
    Syed, Shorabuddin
    Paydak, Hakan
    Mehta, Jawahar L.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2019, 24 (05) : 428 - 434
  • [4] Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation
    Gustafson, Whitney L.
    Saunders, John
    Vazquez, Sara R.
    Jones, Aubrey E.
    Witt, Daniel M.
    [J]. PHARMACY PRACTICE-GRANADA, 2019, 17 (04):
  • [5] Recurrent Strokes in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Agents
    Frol, Senta
    Hudnik, Liam K.
    Sernec, Lana P.
    Sabovic, Miso
    Popovic, Katarina Surlan
    Oblak, Janja Pretnar
    [J]. ANGIOLOGY, 2023, 74 (04) : 344 - 350
  • [6] Real-world Evaluation of Healthcare Resource Use and Costs of Elderly Patients with Nonvalvular Atrial Fibrillation Treated with Apixaban vs. Warfarin in the US
    Deitelzweig, S.
    Luo, X.
    Gupta, K.
    Trocio, J.
    Mardekian, J.
    Lingohr-Smith, M.
    Menges, B.
    Lin, J.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S79 - S80
  • [7] Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?
    Liu, Xuyang
    Feng, Shenghui
    Chen, Zhuohui
    Zhou, Yue
    Yin, Kang
    Xue, Zhengbiao
    Zhu, Wengen
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [8] Comparison of healthcare costs among patients with non-valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant
    Franchino-Elder, Jessica
    Gilligan, Adrienne
    Song, Xue
    Hartaigh, Briain O.
    Henriques, Caroline
    Sainski-Nguyen, Amy
    Wang, Cheng
    [J]. JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2020, 11 (02) : 133 - 140
  • [9] REAL-WORLD EVIDENCE ON CLINICAL USE OF A NOVEL ORAL ANTICOAGULANT FOR THE TREATMENT OF ATRIAL FIBRILLATION
    Verdecchia, P.
    Lanati, E. P.
    Verdini, V.
    Corrao, G.
    Scotti, L.
    Airoldi, C.
    Iorio, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A625 - A625
  • [10] Pharmacogenetics of warfarin and healthcare costs - Real-world data analysis
    Lahteenmaki, Jaakko
    Vuorinen, Anna-Leena
    Lehto, Mika
    Niemi, Mikko
    Forsberg, Markus M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (03) : 382 - 386
12345